Evidence map›Paper›PMID 25165102›Full record

ArticleJournal of virology2014

Emergence of individual HIV-specific CD8 T cell responses during primary HIV-1 infection can determine long-term disease outcome.

Hendrik Streeck, Richard Lu, Noor Beckwith, Mark Milazzo, Michelle Liu, Jean-Pierre Routy, Susan Little, Heiko Jessen, Anthony D Kelleher, Frederick Hecht and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Mucosal immunity in acute HIV: a review of recent work.Current opinion in HIV and AIDS · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Suboptimal Immune Reconstitution among HIV-Infected Saudi Patients following Successful Antiretroviral Treatment.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2019
    Article
  9. Article
  10. Analysis of the CD8Immunogenetics · 2018
    Article
  11. Article
  12. Article
  13. Conserved HIV Epitopes for an Effective HIV Vaccine.Journal of clinical & cellular immunology · 2017
    Article
  14. Role of Different Subpopulations of CD8Frontiers in immunology · 2017
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 4 countries.

Hendrik StreeckU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA hstreeck@hivresearch.org.
Richard LuU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Noor BeckwithHarvard School of Medicine, Boston, Massachusetts, USA.
Mark MilazzoU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Michelle LiuU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA.
Jean-Pierre RoutyMcGill University, Division of Hematology and Immunodeficiency Service, Royal Victoria Hospital, Montreal, Quebec, Canada.
Susan LittleDepartment of Medicine, University of California, San Diego, San Diego, California, USA.
Heiko JessenHIV Clinic Praxis Jessen, Berlin, Germany.
Anthony D KelleherKirby Institute, UNSW, Sydney, New South Wales, Australia.
Frederick HechtDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, California, USA.
Rafick-Pierre SekalyDivision of Infectious Diseases, Vaccine and Gene Therapy Institute-Florida, Port Saint Lucie, Florida, USA.
Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.
David HeckermaneScience Group, Microsoft Research, Los Angeles, California, USA.
Mary CarringtonRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Eric S RosenbergMassachussetts General Hospital, Boston, Massachusetts, USA.
Marcus AltfeldRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA Heinrich-Pette-Institute, Hamburg-Eppendorf, Germany.
Henry M. Jackson Foundation · USWalter Reed Army Institute of Research · USFrederick National Laboratory for Cancer Research · USHarvard University · USMassachusetts General Hospital · USMicrosoft (United States) · USOrthopädische Praxis · DERagon Institute of MGH, MIT and Harvard · USRoyal Victoria Hospital · CAUniversität Hamburg · DEUniversity of California, San Diego · USUniversity of California, San Francisco · USUNSW Sydney · AUVaccine & Gene Therapy Institute of Florida · US

Funding

Primary Infection Resource Consortium (PIRC)R24AI106039 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LITTLE, SUSAN JANET · 2013 to 2021
$23.1M
Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
Recognition of HIV-1 by Innate Immunity Receptors during Primary InfectionP01AI074415 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2008 to 2013
$17.3M
Modulation of HIV-specific CD8+ T and B cell function by CD4+ T helper responsesR01AI091450 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI STREECK, HENDRIK · 2010 to 2013
$1.7M
T follicular helper cells: Role in generation of anti-HIV antibody responsesR01AI094602 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI STREECK, HENDRIK · 2011 to 2015
$1.6M
CCR NIH HHS HHSN261200800001CCIHRIntramural NIH HHSNCI NIH HHS HHSN261200800001ENIAID NIH HHS NIH P01 AI074415NIAID NIH HHS P01 AI074415NIAID NIH HHS R01 AI091450NIAID NIH HHS R01 AI091450-01NIAID NIH HHS R01 AI094602NIAID NIH HHS R01 AI094602-01NIAID NIH HHS R24 AI106039
6 · The paper itself

Abstract

unlabelledEvents during primary HIV-1 infection have been shown to be critical for the subsequent rate of disease progression. Early control of viral replication, resolution of clinical symptoms and development of a viral set point have been associated with the emergence of HIV-specific CD8 T cell responses. Here we assessed which particular HIV-specific CD8 T cell responses contribute to long-term control of HIV-1. A total of 620 individuals with primary HIV-1 infection were screened by gamma interferon (IFN-γ) enzyme-linked immunospot (ELISPOT) assay for HLA class I-restricted, epitope-specific CD8 T cell responses using optimally defined epitopes approximately 2 months after initial presentation. The cohort was predominantly male (97%) and Caucasian (83%) (Fiebig stages II/III [n = 157], IV [n = 64], V [n = 286], and VI [n = 88] and Fiebig stage not determined [n = 25]). Longitudinal viral loads, CD4 count, and time to ART were collected for all patients. We observed strong associations between viral load at baseline (initial viremia) and the established early viral set points (P < 0.0001). Both were significantly associated with HLA class I genotypes (P = 0.0009). While neither the breadth nor the magnitude of HIV-specific CD8 T cell responses showed an influence on the early viral set point, a broader HIV-specific CD8 T cell response targeting epitopes within HIV-1 Gag during primary HIV-1 infection was associated with slower disease progression. Moreover, the induction of certain HIV-specific CD8 T cell responses--but not others--significantly influenced the time to ART initiation. Individual epitope-specific CD8 T cell responses contribute significantly to HIV-1 disease control, demonstrating that the specificity of the initial HIV-specific CD8 T cell response rather than the restricting HLA class I molecule alone is a critical determinant of antiviral function. IMPORTANCE: Understanding which factors are involved in the control of HIV-1 infection is critical for the design of therapeutic strategies for patients living with HIV/AIDS. Here, using a cohort of over 600 individuals with acute and early HIV-1 infection, we assessed in unprecedented detail the individual contribution of epitope-specific CD8 T cell responses directed against HIV-1 to control of viremia and their impact on the overall course of disease progression.

Indexed as

CD4 Lymphocyte CountCD8-Positive T-LymphocytesEnzyme-Linked Immunospot AssayFemaleHIV-1HIV InfectionsHumansInterferon-gammaLongitudinal StudiesMaleTime FactorsTreatment OutcomeViral LoadInterferon-gamma

Identifiers

PMID25165102
PMCPMC4248916
OpenAlexW2150741865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.